KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Receivables (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Receivables for 6 consecutive years, with $140.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 74.93% year-over-year to $140.2 million, compared with a TTM value of $140.2 million through Dec 2025, up 74.93%, and an annual FY2025 reading of $140.2 million, up 74.93% over the prior year.
  • Receivables was $140.2 million for Q4 2025 at Esperion Therapeutics, up from $119.0 million in the prior quarter.
  • Across five years, Receivables topped out at $140.2 million in Q4 2025 and bottomed at $21.7 million in Q3 2021.
  • Average Receivables over 5 years is $54.3 million, with a median of $41.7 million recorded in 2023.
  • The sharpest move saw Receivables surged 85.13% in 2021, then grew 12.86% in 2022.
  • Year by year, Receivables stood at $22.9 million in 2021, then soared by 47.07% to $33.7 million in 2022, then skyrocketed by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then skyrocketed by 74.93% to $140.2 million in 2025.
  • Business Quant data shows Receivables for ESPR at $140.2 million in Q4 2025, $119.0 million in Q3 2025, and $107.7 million in Q2 2025.